Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
339.43
-1.04 (-0.31%)
Feb 27, 2026, 12:00 PM EST - Market open
PRAX Employees
Praxis Precision Medicines had 168 employees as of December 31, 2025. The number of employees increased by 52 or 44.83% compared to the previous year.
Employees
168
Change (1Y)
52
Growth (1Y)
44.83%
Revenue / Employee
n/a
Profits / Employee
-$1,805,167
Market Cap
9.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 168 | 52 | 44.83% | 168 | 0 |
| Dec 31, 2024 | 116 | 34 | 41.46% | 116 | 0 |
| Dec 31, 2023 | 82 | -27 | -24.77% | 82 | 0 |
| Dec 31, 2022 | 109 | -30 | -21.58% | 109 | 0 |
| Dec 31, 2021 | 139 | 72 | 107.46% | 139 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Jazz Pharmaceuticals | 2,800 |
| Madrigal Pharmaceuticals | 915 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 498 |
| Halozyme Therapeutics | 423 |
| Vaxcyte | 414 |
PRAX News
- 7 days ago - Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
- 7 days ago - Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 17 days ago - Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - Business Wire
- 5 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 7 weeks ago - Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - GlobeNewsWire